The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02510261.

Trial PhasePhase III

Trial Typetreatment

Lead OrganizationAlnylam Pharmaceuticals

• Primary IDALN-TTR02-006
• Secondary IDsNCI-2017-00574, 2014-003877-40
• ClinicalTrials.gov IDNCT02510261